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There is international variation in hospital admission practices for patients with mild 
traumatic brain injury (TBI) and injuries on CT scan. Only a small proportion of patients 
require neurosurgical intervention, while many guidelines recommend routine admission of 
all patients. We aim to validate the Hull Salford Cambridge Decision Rule (HSC DR) and the 
Brain Injury Guideline (BIG) criteria to select low risk patients for discharge from the 
Emergency Department.
Method
A cohort from 18 countries of GCS 13-15 patients with injuries on CT imaging was identified 
from the multi-centre CENTER-TBI study (conducted 2014 - 2017) for secondary analysis. A 
composite outcome measure encompassing need for ongoing hospital admission was used, 
including seizure activity, death, intubation, neurosurgical intervention, and neurological 
deterioration. We assessed the performance of our previously derived prognostic model, 
the HSC DR and the BIG criteria at predicting deterioration in this validation cohort.
Results
Among 1047 patients meeting the inclusion criteria, 267 (26%) deteriorated. Our prognostic 
model achieved a C-statistic of 0.81 (95% CI, 0.78 to 0.84). The HSC DR achieved a sensitivity 
of 100% (95% CI: 97% to 100%) and specificity of only 4.7% (95% CI: 3.3% to 6.5%) for 
deterioration. Using the BIG criteria for discharge from the ED achieved a higher specificity 
(13.3%, 95% CI: 10.9% to 16.1%) and  lower sensitivity (94.6%, 95% CI: 90.5 % to 97%), with 



































































12/105 patients recommended for discharge subsequently deteriorating,  compared to 0/34 
with the HSC DR.
Conclusion
Our decision rule would have allowed 3.5% of patients to be discharged, none of whom 
would have deteriorated. Use of the BIG criteria may result in too high a risk of 
deterioration in a discharged patient to be used clinically. Further validation and 
implementation studies are required to support use in clinical practice.
What is already known on this subject
NICE head injury guidelines state that following head injury, patients with “new, clinically 
significant abnormalities on imaging” should be admitted for observation without defining 
which injuries are clinically significant. We have previously empirically derived the first 
prognostic model and decision rule (HSC-DR) to identify low risk patients with injuries on CT 
who could be safely discharged from the ED.
What this Study adds
We present the first validation study of our prognostic model and the HSC-DR. It shows that 
application of the HSC-DR may allow a modest but safe reduction in inpatient admissions of 
selected low risk patients with traumatic brain injuries identified by CT imaging.
Keywords: Mild Traumatic Brain Injury; Prognostic Model; Clinical Decision Rule; Emergency 
Department; Head Injury




































































Over 2 million patients are admitted to hospital each year across Europe for traumatic brain 
injury (TBI; injury to the brain or alteration of brain function due to external force).1 95% of 
patients admitted to hospital and 36% of patients admitted to intensive care units with TBI 
have an initial Glasgow Coma Scale (GCS) of 13-15 and are defined as having mild injuries.2 
The management of mild TBI patients with injuries identified by CT imaging is controversial.
Around 7% of initial GCS13-15 patients who present with head trauma have intra-cranial 
injuries or skull fractures identified on CT imaging but only around 1% of patients die or 
require neurosurgery.3 Some studies advocate routine admission under specialist 
neurosurgical care and repeat CT imaging of all mild TBI patients with injuries identified on 
CT.4 5 Some North American centres have adopted the consensus derived Brain Injury 
Guideline (BIG) criteria which advocates the discharge of selected patients from the ED  
(Supplementary Material 1).6 In Europe there is variation in clinical practice with patients 
admitted under a range of specialties and with varying levels of intensity of inpatient care.2 
We recently developed the first empirically derived prognostic model and decision rule (the 
Hull Salford Cambridge Decision Rule (HSC DR)) predicting need for hospital admission in 
this population.7 We compared the performance of the HSC DR and BIG criteria and found 
both had high sensitivity to clinical deterioration. The HSC DR maximised sensitivity at a cost 
of a specificity of 7% at the discharge threshold to ensure clinical safety, but implementation 
would have recommended fewer than one in ten TBI patients be discharged. 7 However, in 
the “COVID 19” era - where reducing hospital acquired infections is paramount, and in other 
resource constrained contexts, even small reductions in unnecessary hospital admissions 
are valuable. Application of this decision rule could – if externally validated – achieve this.7 



































































The aims of this study were:
1. Externally validate and compare the performance of the HCS and BIG criteria 
decision rules, using an international dataset of patients attending Emergency 
Departments following traumatic brain injury. 
2. Evaluate the performance of the HCS and BIG criteria decision rules for mildly injured 
patients with TBI.
3. Externally vali ate the empirically derived prediction model underpinning HSC-DR 
(recalibrating where required) using the CENTER TBI cohort. 
Methods
Study design 
An international dataset of patients with CT diagnosed TBI, was used to externally validate 
the two decision rules (BIG and HSC-DR) by comparing their sensitivity and specificity for 
predicting which patients required hospital admission for specific treatments.2 8 The 
CENTER-TBI dataset was then used to recalibrate the HSC prediction model (which then 
feeds into the decision rule). The aim of the recalibration was to determine if the HSC 
decision rule performance could be improved using data from a more diverse population 
compared to the initial derivation dataset. We followed international guidelines (TRIPOD) 
for reporting of prognostic model validation.8 The methods used to derive our prognostic  
model and the HSC-DR are available in the previously published protocol and derivation 
studies.7 9 




































































Data for the core CENTER-TBI study were collected between December 2014 and 2017 at 63 
centres across Europe and Israel and 4509 patients of all TBI severity were recruited, 
stratified by three strata of planned clinical management: ED only, admitted initially as a 
ward inpatient and admitted initially to intensive care. All patients were initially managed in 
the Emergency Department. Data were prospectively collected by trained research staff as 
detailed in the study protocol.10. Follow up data were collected at 2-3 weeks, 3 months and 
6 months with data collected on 83.4% of patients at 6-months.
Inclusion and exclusion criteria
Patients aged 16 and over with an initial GCS 13-15 recorded in the ED and with either a 
skull fracture, intra-cranial haemorrhage or cerebral contusion identified on first CT scan -
regardless of care pathway stratum were included, reflecting the population used in our 
derivation study.7 Patients where initial GCS in the ED was unknown and patients where 
diffuse axonal injury was the sole injury identified on initial CT scan were excluded. 
Outcome
A composite outcome encompassing need for hospital admission was defined, matching the 
outcome in the model derivation study. This included: seizure as inpatient or at 2 week 
follow-up, death attributed to TBI within 30 days of first attendance, intubation recorded 
within 30 days of presentation, admission to ICU for any reason apart from close 
monitoring, neurosurgical intervention and recorded neurological deterioration (new deficit 
or drop in GCS of more than 1 point). 




































































The original extended prediction model includes seven predictor variables for a composite 
outcome of deterioration encompassing need for hospital admission in this TBI population 
(Table 1).7 The full prediction model is available in Supplementary Material 2. Six of these 
variables were used in our derivation study to form the simplified HSC DR which could be 
applied clinically to identify patients who could be safely discharged from the ED (Table 1 
and Supplementary Material 2). The BIG criteria use 6 factors to risk stratify patient 
management (Supplementary Material 1). All factors in the prediction model and BIG 
criteria were available from data collected in CENTER-TBI.
Table 1: Factors in extended prognostic model and HSC DR
Factors in Extended model HSC DR
Discharge if
BIG Criteria
Discharge after 6 hours if
Preinjury Anti-coagulation or anti-
platelets
No No
Initial GCS 13-15 GCS 15 13-15
First Neurological Examination Normal Normal 
Number of Injuries on CT:
1-5 or Diffuse
1
Injury severity on CT:
Simple skull fracture
Complex Skull Fracture
Marshall IIa 1-2 bleeds < 5mm (total)




Simple Skull fracture or 1-
2 bleeds< 5mm total
Subdural ≤ 4mm
Extradural ≤ 4mm







Injury Severity Score (body regions 
excluding head)
Up to 2 non-significant 
extra-cranial injuries(not 
requiring impatient care, 
e.g closed fracture 
humerus)                    
Intoxication Not intoxicated
Hb Not included in risk score




































































A minimum of between 100-200 events and 100-200 non-events per study sample has been 
recommended for validation studies of logistic regression models.11 12 The validation cohort 
contained over 200 events and non-events.
Missing data
To evaluate model performance, missing data were multiply imputed using the ICE STATA 
package on the assumption they were missing at random (fully described Supplementary 
Material 3).13  Performance was averaged across imputed data sets.14 15 
Decision Rule Performance
All analysis was completed using STATA 16 (StataCorp. 2019. Stata Statistical Software: 
Release 16. College Station, TX: StataCorp LLC). Sensitivity, specificity of the HSC DR and of 
the BIG criteria to the composite outcome of deterioration were calculated in patients with 
complete data for either criteria. To be recommended for discharge all components of HSC 
DR or BIG criteria (Table 1) must be fulfilled. The proportion of patients recommended for 
discharge and accompanying risk of deterioration in a discharged patient (negative 
predictive value) were compared. In pre-specified exploratory subgroup analysis this was 
repeated in patients with less severe injuries as indicated by having a brain abbreviated 
injury score (AIS) or Marshall classification <3.16  This represents patients without obvious 
midline shift or severe injuries on CT imaging and the population admitted for observation 
under ED care in the UK. 
Model performance and recalibration



































































Performance of the prediction model was assessed in the CENTER-TBI cohort using 
measures of discrimination and calibration. Discrimination indicates how well the model 
differentiates between patients who deteriorated and those who do not deteriorate and 
was measured using the C-statistic (equivalent to the area under ROC curve).17 
Calibration measures how closely predictions made by the model match observed outcomes 
(i.e. do predicted mean outcomes match observed mean outcomes).17 Calibration was 
assessed visually using a calibration plot and with estimates of the “calibration in the large” 
(the ratio of expected versus observed numbers of events) and  slope of the calibration plot 
(the overall prognostic effects of predictors in the model). To account for differences 
between the derivation and validation cohort and potential model over-fitting during 
derivation, the intercept and coefficients of the prediction model were also re-estimated to 
provide a re-calibrated model. 
Clinical usefulness
Decision curve analysis was used to estimate the net benefit of using the prognostic model 
to select patients for discharge from the ED.18 19 Net benefit is estimated by the number of 
true positives minus false positives multiplied by the clinical weight given to correct 
classification across a range of probabilities of deterioration where discharge could be 
considered.19 The net benefit of using the prognostic model was compared visually in curves 
using the BIG criteria’s single decision threshold and reference strategies of discharging no 
or all patients.20 
Ethics



































































Ethics approval was obtained for each recruiting site, full details are available here 
https://www.center-tbi.eu/project/ethical-approval. .
Patient and Public Involvement
The Hull and East Yorkshire NHS Trust Trans-Humber Consumer Research Panel and Hull 
branch of the Headway charity helped inform developing the overall research aim of 
developing a predictive model to identify low risk patients with injuries on CT imaging who 
could be safely discharged from the ED. 
Results 
Study population
The cohort (n=1047) was mostly male, with over a third of patients aged over 65 and over 
20% with either pre-injury anti-coagulant or anti-platelet use (Figure 1, Table 2). A total of 
379 (36%) patients had data missing from at least one predictor variable value (mostly initial 
haemoglobin) used in the full prognostic model (Table 2). 12.1% patients had data missing in 
one or more predictor variable used in the HSC DR.  Any clinical deterioration was noted 
among 267 patients (26%; 95% CI: 23% to 28%), including 212 patients (20%; 95% CI: 178% 
to 23%) who underwent neurosurgery, died, or were intubated and 25 patients had deaths 
attributable to TBI. 



































































Table 2: Characteristics of the study population (N=1047)
Population 
Characteristic
Category Mean (SD), min-max or 
N (%)
Missing data
Age Years 54.8 (SD=19.7)
16-96
None




















Mechanism of Injury High Velocity Trauma
 Blow to head/struck by 
object
Ground level fall






















Yes 152 (14.5%) 71 (6.8%)
Haemoglobin Grams/litre 135 (SD 19.9)
47-23.4
325 (31%)
















Injury severity on CT
(Modified Marshall 
Classification described 
in detail Supplementary 
Material 2)
1) Simple Skull Fractures
2) Complex Skull 
fractures
3)1-2 bleeds < 5mm 
(total)
4) No or minimal mass 
effect














ISS Body regions excluding 
head
17.3  (SD 20.6)
1-75 (range)
9 (0.9%)




































































The HCS DR achieved a sensitivity of 100% (95% CI: 988% to 100%), but very low specificity 
of 4.7% (95% CI: 3.3% to 6.5%) for the composite outcome of deterioration (Table 3). BIG 1 
classification missed some events (sensitivity 94.6%, 95% CI: 90.5 % to 97%), but had higher 
specificity (13.3%, 95% CI: 10.9% to 16.1%). Application of the HSC DR would have 
recommended discharge of only 3.5% of patients, compared to 11.4% patients 
recommended by the BIG criteria. However, patients recommended for discharge by the 
BIG criteria had a 11.4% (95% CI: 6.7 % to 18.9%), risk of subsequent deterioration, 
compared to 0% (95% CI: 0 % to 10.2%) with the HSC DR. 
Table 3: Performance of BIG and HSC Decision Rules *
BIG Criteria Performance
N=921 Deteriorated Didn’t deteriorate
 BIG1 (discharge from ED 
after 6 hours)
12 93 Sensitivity 94.6% (90.5- 
97%)
Negative Predictive Value
88.6% (80.5 - 93.7%)
BIG 2/3 (admit) 210 606 Specificity 13.3% (10.9% - 
16.1%)
Positive Predictive Value
25.7% (22.8 - 28.9%)
HSC DR
N=961 Deteriorated Didn’t Deteriorate
Risk=0 (discharge) 0 34 Sensitivity 100% (988-100%)
Negative Predictive Value
100% (87.4 - 100%)
Risk>0 (admit) 234 693 Specificity 4.7% (3.3-6.5%)
Positive Predictive Value
25.2% (22.5 - 28.2%)
*Full performance of the BIG are presented in Supplementary Material 4 and characteristics 
of patients recommended for discharge in Supplementary Material 5



































































Sub-group analysis of less severely injured patients
 One hundred and forty-six patients had AIS<3 and 800 patients had Marshall Classification 
<3 injuries. Use of the HSC DR would have facilitated discharge of 23% (34/146) of patients 
with brain AIS < 3, and 4.25% (34/800) of patients with Marshall Classification <3 injuries. 
No patients selected for discharge by the HSC DR deteriorated (risk of deterioration 0%, 95% 
CI: 0% to 10.2%). Use of BIG criteria would have selected 26% (37/142) of patients with 
brain AIS < 3 injuries for discharge but with an 8.1% (95% CI: 2.8 % to 21.3%) risk of 
deterioration and 13.6% (105/770) of patients with Marshall classification < 3 injuries but 
with an 11.4% (95% CI: 6.7% to 18.9%) risk of deterioration (Table 4 and Supplementary 
Material 6).
Table 4: Subgroup analysis AIS<3
HSC DR
N=146 Deteriorated Didn’t deteriorate
Risk=0 (discharge) 0 34 Sensitivity 100% (69.99-
100%)
Negative Predictive Value
100% (87.4 - 100%)
Risk>0 (admit) 12 100 Specificity 25.4% (18.4-
33.8%)
Positive Predictive Value
10.7% (1075.9 - 18.313%)
BIG 1 
N=142 Deteriorated Didn’t deteriorate
BIG1 (discharge from ED 
after 6 hours)
3 34 Sensitivity 75% (42.8-93.3%)
Negative Predictive Value
91.9% (77 – 97.9%)
BIG 2/3 (admit) 9 96 Specificity 26.2 (19-34.7%)
Positive Predictive Value
8.6% (4.2 – 16.1%)



































































Twenty-seven patients were excluded from the cohort as the only injury identified on initial 
CT imaging were diffuse axonal injury and therefore, they could not be assigned to a BIG 
criterion. These injuries are equivalent to a Marshall score 4 severity and would be 
recommend for admission by the HSC DR. Sensitivity analysis including these patients found 
the HSC DR achieved a sensitivity (100% 95% CI: 98% to 100%) and specificity (4.5% 95% CI: 
3.2% to 6.3%) to the composite outcome of deterioration.
Model Performance
The original prognostic model achieved a C-statistic of 0.81 (95% CI, 0.78 to 0.84) in the 
CENTER-TBI cohort (0.75 in the deve opment cohort) and an estimated slope of the 
calibration plot of 0.51 in the CENTER-TBI cohort (0.86 in the development cohort) (Figure 
2i). The effect of re-calibration of both the intercept and coefficients is presented in Figure 
2ii and the recalibrated model is presented in Supplementary Material 7. Measures of 
calibration improved but the estimated C-statistic of the recalibrated model remained 0.81.
Clinical usefulness, analysis according to clinical tolerance for adverse outcomes  
Clinical usefulness depends on tolerance of risk of deterioration in those discharged without 
observation. Figure 3 presents the decision curves and net benefit analysis for the selection 
of patients either for a period of inpatient hospital observation or discharge directly from 
the ED using the recalibrated prognostic model or BIG criteria in the CENTER-TBI cohort. Due 
to the high risk of harm associated with discharging a patient who subsequently 
deteriorates, the analysis was limited to those with a low predicted probability of 
deterioration. Use of our recalibrated model showed potential benefit over an ‘admit all’ 



































































strategy if the threshold for the predicted probability of deterioration was over 2% (Figure 
3), which is potentially an acceptable clinical risk of deterioration in a discharged patient. If 
2% is considered too high a risk to discharge a patient, given the harm associated with 
deterioration in the community, then no net benefit over an “admit all” strategy was 
demonstrated. The BIG criteria showed benefit over an ‘admit all’ strategy up to a threshold 
for predicted probability of deterioration of around 12%.
Discussion 
Summary
This study validated the performance of the BIG and HSC decision rules in a large 
international dataset of patients with TBI, who had an overall deterioration prevalence of 
26% (95%CI 23%, 28%). The BIG criteria achieved a sensitivity of 94.6% (95% CI: 90.5 % to 
97%) and specificity of 13.3% (95% CI: 10.9% to 16.1%) and would have recommended 
discharge of 11% of patients with an accompanying risk of subsequent deterioration of 
11.4% (95% CI: 6.7 % to 18.9%). The HSC DR achieved a sensitivity of 100% (95% CI: 98% to 
100%) and specificity of 4.7% (95% CI: 3.3% to 6.5%), comparable to that reported in the 
development cohort (99.5% and 4.8% respectively). The HSC DR would have recommended 
discharge of 3.5% of patients but with a subsequent risk of deterioration of 0% (95% CI: 0 % 
to 10.2%). The prognostic model that underpins the HSC DR achieved a C-statistic of 0.81 
and re-calibration improved accuracy of individual predicted risk of deterioration 
(calibration). 
In the subgroup of patients with less severe injuries who are more likely to admitted under 
non-specialist teams the BIG criteria recommended discharge of 26% of patients with brain 



































































AIS < 3 injuries for discharge but with an 8.1% (95% CI: 2.8 % to 21.3%) risk of deterioration. 
The HSC DR recommended discharge of 23% of patients of patient in this group with a risk 
of subsequent deterioration of 0% (95% CI: 0% to 10.2%). 
Strengths 
 This study is the first external validation of the HSC-DR and, alongside our previous 
development study, is the largest study to externally validate the BIG criteria and only study 
to do so in a multi-centre European cohort of patients.4 21-23 The CENTER-TBI study has good 
prospective patient follow-up and so significant adverse outcomes in the community were 
unlikely to have been missed. We have adhered to international guidelines for model 
validation.8 We explicitly addressed the potential clinical usefulness of the decision rule and 
prognostic model according to a range of potential thresholds. This decision curve analysis 
clarified that if quite low risks were already considered too high, e.g. corresponding to a 
threshold of 1%, a treat all strategy would dominate. On the other hand, a less risk averse 
clinical policy, such as accepting risks up to 10% as acceptable, would lead to greater value 
of our rule or model (Fig 3). 
Limitations
Previous studies estimated that around 10% of initial GCS13-15 patients have skull fractures 
or intra-cranial injures identified on CT imaging, whilst in the CENTER-TBI study around 50% 
of patients have injuries identified on imaging.3 24 25 The CENTER-TBI population may be a 
higher risk group  than the clinical population assessed in the ED. There was a relatively high 
proportion of missing data, especially for haemoglobin values. However, it is likely these 
data were missing at random, i.e. only related to observed variables, and that imputation 



































































methods we used are valid. Study recruitment for CENTER-TBI occurred at 2 sites 
(Cambridge and Salford) at which the case note review for derivation of our prognostic 
model was conducted. These sites only contributed 6.9% of patients to the CENTER-TBI 
validation cohort and exclusion of these patients did not materially affect our results 
(Supplementary Material 8). Determining the significance of extra-cranial injuries in the 
HSC-DR as derived from extra-cranial ISS score (including facial injuries) requires some 
subjective clinical judgement.  
Comparison to previous literature
In the CENTER TBI cohort, 20% of patients underwent neurosurgery, died, or were intubated 
compared to 13.1% in our development cohort and had a higher prevalence of deterioration 
than reported in a previous systematic review. 4  This may reflect recruitment of more 
severely injured patients to the CENTER-TBI study.
The BIG criteria for discharging patients from the ED achieved a lower sensitivity (94.6%) 
and higher specificity (13.3%) than when applied to our development cohort (sensitivity 
99.5% and specificity 4.8%). Application of the BIG criteria would have allowed 11.4% of 
patients to be discharged from the ED which is similar to the 10% of patients estimated in 
studies conducted where the BIG criteria was developed in the USA and 15% reported in an 
external validation study.6 21 23 The derivation and validation studies reported by the team 
that developed the BIG criteria and available external validation studies report no adverse 
outcomes in patients recommended for discharge by the BIG criteria.6 21-23 26  In the CENTER-
TBI cohort, patients recommended for discharge had a 11.4% (95% CI: 6.7 % to 18.9%), risk 



































































of subsequently deteriorating. This may reflect the broader composite outcome measure 
used in our study and more comprehensive prospective follow-up of patients for 
deterioration. Some validation studies also modified the BIG criteria so that any patient with 
an initial GCS <15 was admitted to hospital.22 The USA TBI population used for these studies 
also appears to be lower risk with a lower reported average age, anti-coagulant use and 
neurosurgical intervention rate.4 23 The risk of deterioration when discharging a patient from 
the ED that is acceptable to patients and clinicians is subjective. When deriving the HSC-DR7 
we aimed to maximise s nsitivity and aimed for a risk of a discharged patient deteriorating 
of around 1%, as this corresponds to other decision rules for discharging patients from the 
ED,25 27 and may be a sufficiently low risk to consider routine discharge. However, significant 
variation in risk tolerance in clinicians and public representatives has been demonstrated, 
with some indicating that even a 1% risk of deterioration may be too high.28 29  Implications
There is variation internationally in management and admission practices in this TBI 
population.4 In the UK and other European countries guidelines recommend admission of all 
patients with TBI identified on CT imaging. This validation study shows a recalibrated version 
of our prognostic model could allow accurate prediction of risk of deterioration, and 
application of the HSC DR would have allowed a modest but safe reduction in hospital 
admissions for this group. The application of the BIG criteria would have discharged more 
patients but with a higher risk of subsequent deterioration in this European population, 
which may not be clinically acceptable. As indicated by our exploratory sub-group analysis, 
application of the HSC DR may be more beneficial when applied to lower risk populations 
more reflective of patients who attend the ED and are admitted for observation under 
Emergency Medicine or other non-neurosurgical specialities in the UK. 



































































Our net benefit analysis using decision curves (Figure 3) showed use of our prognostic 
model may show benefit over an ‘admit all’ strategy if the threshold for the predicted 
probability of deterioration was over 2% and patients selected for discharge by the HSC DR 
had a 0% (95% CI: 0 % to 10.2%) risk of deterioration. This may be sufficiently low risk to use 
routinely. Research is needed to assess clinician and patient risk appetite in this population 
and assess the clinical impact of implementing the HSC DR where patient circumstances like 
intoxication or social circumstances may further affect whether a patient can be discharged. 
Research to improve the accuracy of the prognostic model (e.g. through including 
biomarkers, other novel prognostic factors, or better classification of injury severity on CT 
imaging) is also needed. .
Conclusion
Use of the HSC DR would allow a modest but safe reduction in hospital admissions for mild 
TBI patients with injuries identified on CT. The BIG criteria appear to result in an 
unacceptably high risk of subsequent deterioration (one in ten) among discharged patients. 
Future research should further validate our prognostic model and the HSC DR, consider safe 
implementation into clinical practice and assess whether inclusion of novel prognostic 
factors could improve the specificity of the model allowing more patients to be safely 
discharged. 
Author Disclosure Statement:
No competing financial interests exist.
Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a 
large collaborative project with the support of the European Union 7th Framework program 
(EC grant602150). Full list of participants and investigators are provided in Supplementary 



































































Material 9. Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), 
from OneMind (USA) and from Integra LifeSciences Corporation (USA) (Grant Number Not 
Applicable/NA).
FEL and EWS are supported by the European Union Framework 7 Collaborative European 
Neurotrauma Effectiveness Research in Traumatic Brain Injury ((EC grant 602150)). FEL is 
also supported by the NHS Trusts "Trauma Audit and Research Network - 
www.tarn.ac.uk"(Grant Number Not Applicable/NA).
CM is a National Institute for Health Research (NIHR) Clinical Lecturer in Emergency 
Medicine (Grant Number Not Applicable/NA). This publication presents independent 
research funded by the National Institute for Health Research and University of Sheffield. 
The views expressed are those of the author(s) and not necessarily those of the University of 
Sheffield, the NHS, the NIHR or the Department of Health and Social Care
Authors' contributions:
The idea for the study was conceived by CM, TAS and FEL. The analysis was completed by 
CM with specialist statistical advice from BYG and EWS and specialist clinical advice from 
FEL. All authors contributed to interpretation of results, read and approved the final 
manuscript.
Figures:
Figure 1: STROBE flow diagram of selection of study population
Figure 2:  Slope of the calibration plot of original and re-calibrated  prognostic model
Figure 3: Decision Curve analysis




































































1. Majdan M, Plancikova D, Brazinova A, et al. Epidemiology of traumatic brain injuries in Europe: a 
cross-sectional analysis. Lancet Public Health 2016;1(2):e76-e83. doi: 10.1016/S2468-
2667(16)30017-2 [published Online First: 2017/12/19]
2. Steyerberg EW, Wiegers E, Sewalt C, et al. Case-mix, care pathways, and outcomes in patients 
with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, 
cohort study. Lancet Neurol 2019;18(10):923-34. doi: 10.1016/S1474-4422(19)30232-7 
[published Online First: 2019/09/19]
3. Haydel MJ, Preston CA, Mills TJ, et al. Indications for computed tomography in patients with minor 
head injury. N Engl J Med 2000;343(2):100-5. doi: 10.1056/NEJM200007133430204
4. Marincowitz C, Lecky FE, Townend W, et al. The Risk of Deterioration in GCS13-15 Patients with 
Traumatic Brain Injury Identified by Computed Tomography Imaging: A Systematic Review 
and Meta-Analysis. J Neurotrauma 2018;35(5):703-18. doi: 10.1089/neu.2017.5259 
[published Online First: 2018/01/13]
5. Thomas BW, Mejia VA, Maxwell RA, et al. Scheduled repeat CT scanning for traumatic brain injury 
remains important in assessing head injury progression. J Am Coll Surg 2010;210(5):824-30, 
31-2. doi: 10.1016/j.jamcollsurg.2009.12.039
6. Joseph B, Friese RS, Sadoun M, et al. The BIG (brain injury guidelines) project: defining the 
management of traumatic brain injury by acute care surgeons. J Trauma Acute Care Surg 
2014;76(4):965-9. doi: 10.1097/TA.0000000000000161
7. Marincowitz C, Lecky FE, Allgar V, et al. Development of a Clinical Decision Rule for the Early Safe 
Discharge of Patients with Mild Traumatic Brain Injury and Findings on Computed 
Tomography Brain Scan: A Retrospective Cohort Study. J Neurotrauma 2019 doi: 
10.1089/neu.2019.6652 [published Online First: 2019/10/08]
8. Collins GS, Reitsma JB, Altman DG, et al. Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis (TRIPOD). Ann Intern Med 2015;162(10):735-6. 
doi: 10.7326/L15-5093-2 [published Online First: 2015/05/20]
9. Marincowitz C, Lecky FE, Townend W, et al. A protocol for the development of a prediction model 
in mild traumatic brain injury with CT scan abnormality: which patients are safe for 
discharge? Diagnostic and Prognostic Research 2018;2(1):6. doi: 10.1186/s41512-018-0027-
4
10. Maas AI, Menon DK, Steyerberg EW, et al. Collaborative European NeuroTrauma Effectiveness 
Research in Traumatic Brain Injury (CENTER-TBI) A Prospective Longitudinal Observational 
Study. Neurosurgery 2014;76(1):67-80.
11. Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Substantial effective sample sizes were 
required for external validation studies of predictive logistic regression models. J Clin 
Epidemiol 2005;58(5):475-83. doi: 10.1016/j.jclinepi.2004.06.017 [published Online First: 
2005/04/23]
12. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a 
multivariable prognostic model: a resampling study. Stat Med 2016;35(2):214-26. doi: 
10.1002/sim.6787 [published Online First: 2015/11/11]
13. Royston P, White IR. Multiple imputation by chained equations (MICE): implementation in Stata. 
J Stat Softw 2011;45(4):1-20.
14. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and 
clinical research: potential and pitfalls. BMJ 2009;338:b2393. doi: 10.1136/bmj.b2393 
[published Online First: 2009/07/01]
15. Nguyen CD, Carlin JB, Lee KJ. Model checking in multiple imputation: an overview and case study. 
Emerg Themes Epidemiol 2017;14:8. doi: 10.1186/s12982-017-0062-6 [published Online 
First: 2017/08/31]



































































16. Association for the Advancement of Automotive Medicine. (2018). Abbreviated Injury Scale: 
2015 Revision (6 ed.). Chicago, IL. 
17. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a 
framework for traditional and novel measures. Epidemiology 2010;21(1):128-38. doi: 
10.1097/EDE.0b013e3181c30fb2 [published Online First: 2009/12/17]
18. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. 
Med Decis Making 2006;26(6):565-74. doi: 10.1177/0272989X06295361 [published Online 
First: 2006/11/14]
19. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for 
development and an ABCD for validation. Eur Heart J 2014;35(29):1925-31. doi: 
10.1093/eurheartj/ehu207 [published Online First: 2014/06/06]
20. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction 
models, molecular markers, and diagnostic tests. BMJ 2016;352:i6. doi: 10.1136/bmj.i6 
[published Online First: 2016/01/27]
21. Ross M, Pang PS, Raslan AM, et al. External retrospective validation of Brain Injury Guidelines 
criteria and modified guidelines for improved care value in the management of patients with 
low-risk neurotrauma. Journal of neurosurgery 2019;133(6):1880-85.
22. Capron GK, Voights MB, Moore III HR, et al. Not every trauma patient with a radiographic head 
injury requires transfer for neurosurgical evaluation: Application of the brain injury 
guidelines to patients transferred to a level 1 trauma center. The American Journal of 
Surgery 2017;214(6):1182-85.
23. Joseph B, Aziz H, Pandit V, et al. Prospective validation of the brain injury guidelines: Managing 
traumatic brain injury without neurosurgical consultation. Journal of Trauma & Acute Care 
Surgery 2014;77(6):984-88. doi: 10.1097/TA.0000000000000428
24. Ibanez J, Arikan F, Pedraza S, et al. Reliability of clinical guidelines in the detection of patients at 
risk following mild head injury: results of a prospective study. Journal of Neurosurgery 
2004;100(5):825-34.
25. Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT Head Rule for patients with minor 
head injury. Lancet 2001;357(9266):1391-6.
26. Azim A, Jehan FS, Rhee P, et al. Big for small: Validating brain injury guidelines in pediatric 
traumatic brain injury. J Trauma Acute Care Surg 2017;83(6):1200-04. doi: 
10.1097/TA.0000000000001611 [published Online First: 2017/06/08]
27. Battle C, Hutchings H, Lovett S, et al. Predicting outcomes after blunt chest wall trauma: 
development and external validation of a new prognostic model. Crit Care 2014;18(3):R98. 
doi: 10.1186/cc13873 [published Online First: 2014/06/03]
28. Than M, Herbert M, Flaws D, et al. What is an acceptable risk of major adverse cardiac event in 
chest pain patients soon after discharge from the Emergency Department?: A clinical survey. 
International Journal of Cardiology 2013;166(3):752-54. doi: 10.1016/j.ijcard.2012.09.171
29. O'Keeffe ST. A cross-sectional study of doctors’, managers’ and public representatives’ views 
regarding acceptable level of risk in discharges from the emergency department. QJM: An 
International Journal of Medicine 2014;108(7):533-38. doi: 10.1093/qjmed/hcu246



































































Figure 1: STROBE flow diagram of selection of study population 
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Figure 2: Calibration slope of original and re-calibration prognostic model 
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Figure 3: Decision Curve analysis 
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Supplementary Material 1: The Brain Injury Guideline (BIG) criteria:
BIG1 (Discharge from 

















Or Focal Neurological 
deficit




Skull Fracture No Non-displaced Displaced


























*Patients must fulfil all the criteria of BIG1 or BIG2 to be categorised as such and are otherwise 
automatically in BIG3


































































Supplementary Material 2: Risk Score
Factor Coefficient Risk Score Value 
Preinjury Anti-coagulation or anti-
platelets





  0 (Vs)
0.4
0.7
GCS 15  0 
GCS 14  1
GCS 13  2
Normal first Neurological Examination   0.45 Abnormal 1.5





5   
Diffuse 












Injury severity on CT
1 simple skull fracture
2 complex Skull Fracture
3 Marshall IIa 1-2 bleeds < 5mm (total)


















ISS (body regions excluding head)   0.2 Up to 2 non-significant extra-
cranial injuries**                       0
Any significant extra-cranial 
injury or 3 or more injuries      2
Hb -0.01 Not included in risk score
Constant -1.38
* Injuries exclude superficial lacerations and abrasions and a significant extra-cranial injury is defined 
as any injury requiring inpatient care
Supplementary Material 3: Procedure for Multi-imputation of missing data
Missing data was assumed to be missing at random. Thirty-five imputed datasets were created on 
the basis of the fraction of missing information (around 35% of patients had missing data in at least 
one predictor variable in the extended prognostic model). The imputation model contained the 
composite outcome of deterioration, all predictive factors in the prognostic model, and additionally, 
age and sex. Model performance was averaged across imputed data sets. 


































































Supplementary Material 4: Performance of BIG criteria across all 3 risk stratification 
categories
BIG Criteria Performance
BIG 1 (Discharge from ED after 6 hours)





BIG 2 (non-specialist admission)





BIG 3 (Neurosurgical Admission, repeat CT imaging)






























































































Intoxicated Yes 0 (0%) 7 (20.6%)













105 (100%) 34 (100%)
Injury severity on CT
(Modified Marshall 
Classification described 
in detail supplementary 
Material )
1) Simple Skull Fractures













































































Supplementary Material 6: Subgroup analysis Marshall Classification <3
HSC DR
N=800 Deteriorated Didn’t deteriorate
Risk=0 0 34 Sensitivity 100% (96.6-100%)
Risk>0 137 629 Specificity 5.1% (3.6-7.2)
BIG 1 (Discharge after 6 hours)
N=770 Deteriorated Didn’t deteriorate
BIG1 12 93 Sensitivity 90.8% (84.2-95)
BIG 2/3 119 546 Specificity 14.6% (12-17.6)


































































Supplementary Material 7: Recalibrated prognostic model
Factor Coefficient 
(optimism adjusted)







  0 (Vs)
0.2
0.36
Normal first Neurological 
Examination 
  0.23





5   
Diffuse 






Injury severity on CT*
1 simple skull fracture
2 complex Skull Fracture



















































































Supplementary Material 8: Sensitivity analysis with 2 sites used in derivation study excluded
HSC DR
N=893 Deteriorated Didn’t deteriorate
Risk=0 0 31 Sensitivity 100% (98-100)
Risk>0 221 641 Specificity 4.6% (3.2-6.6%)
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